These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
517 related items for PubMed ID: 18829912
1. Low incidence of anti-osteoporosis treatment after hip fracture. Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY. J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912 [Abstract] [Full Text] [Related]
2. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY. Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022 [Abstract] [Full Text] [Related]
3. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Cramer JA, Amonkar MM, Hebborn A, Altman R. Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664 [Abstract] [Full Text] [Related]
4. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644 [Abstract] [Full Text] [Related]
5. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S. Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023 [Abstract] [Full Text] [Related]
6. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E. Int J Clin Pharmacol Res; 2004 Aug; 24(1):1-10. PubMed ID: 15575171 [Abstract] [Full Text] [Related]
10. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. Rietbrock S, Olson M, van Staa TP. QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684 [Abstract] [Full Text] [Related]
12. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102 [Abstract] [Full Text] [Related]
14. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O'Malley CD. J Bone Joint Surg Am; 2014 Apr 02; 96(7):e52. PubMed ID: 24695929 [Abstract] [Full Text] [Related]
16. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis. Zarowitz BJ, Cheng LI, Allen C, O'Shea T, Stolshek B. J Am Med Dir Assoc; 2015 Apr 02; 16(4):341-8. PubMed ID: 25726417 [Abstract] [Full Text] [Related]
17. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Ringe JD, Möller G. Rheumatol Int; 2009 Dec 02; 30(2):213-21. PubMed ID: 19430791 [Abstract] [Full Text] [Related]